Why Conmed (CNMD) is a Top Growth Stock for the Long-Term

Conmed (CNMD), a medical technology company, is positioned as a potential growth opportunity despite its Zacks #3 (Hold) Rank, underscored by strong Style Scores including an 'A' for VGM and 'B' for Growth. The company forecasts 7% year-over-year earnings growth for the current fiscal year, supported by recent upward analyst revisions for fiscal 2025 earnings to $4.46 per share and a consistent 9.2% average earnings surprise. These metrics suggest CNMD warrants attention for growth-oriented portfolios.

Analysis

CONMED Corporation (CNMD) presents a profile of a company with solid underlying growth fundamentals currently offset by a neutral market rating. While the stock holds a Zacks #3 (Hold) rank, its quantitative style scores are strong, featuring an 'A' for the composite VGM score and a 'B' for Growth. This growth profile is substantiated by a forecast for 7% year-over-year earnings growth in the current fiscal year and a historical tendency to outperform expectations, as evidenced by an average positive earnings surprise of 9.2%. Forward-looking sentiment from analysts appears to be improving, with two upward earnings estimate revisions for fiscal 2025 in the last 60 days, lifting the consensus estimate to $4.46 per share. These metrics suggest that despite the neutral headline rating, the underlying financial trajectory and analyst sentiment for the medical technology firm are positive, positioning it as a noteworthy candidate for growth-focused portfolios.

Key Decisions for Investors

• Growth-oriented investors should consider CNMD's favorable metrics, including a 7% projected YoY earnings growth and a consistent 9.2% average earnings surprise, as indicators of fundamental strength.
• The neutral Zacks #3 (Hold) rank should be treated as a signal for caution, suggesting that despite positive growth indicators, significant near-term price appreciation may not be a high-conviction thesis at present.
• Monitor for continued upward revisions to fiscal 2025 earnings estimates, as this could be a leading indicator for a potential ratings upgrade and act as a catalyst for the stock.